Abstract A226: Cell-free membrane reconstitution system for cis and trans interaction of T-cell co-receptors and ligands

Yunlong Zhao, E. Hui
{"title":"Abstract A226: Cell-free membrane reconstitution system for cis and trans interaction of T-cell co-receptors and ligands","authors":"Yunlong Zhao, E. Hui","doi":"10.1158/2326-6074.CRICIMTEATIAACR18-A226","DOIUrl":null,"url":null,"abstract":"Immunotherapy, which harnesses the immune system to combat cancers, is a paradigm-shifting approach in oncology. One important branch of immunotherapy is to use drugs to perturb molecular interactions at the T-cell–antigen presenting cell (APC) interface. In particular, antibodies that block the T-cell coinhibitory receptor PD-1 or its ligand PD-L1 have produced unprecedented clinical activities against a subset of human cancers in a fraction of patients. Extending immunotherapy to a larger patient population requires a better understanding of the interaction network at the T-cell-APC interface. Typically, it is believed that ligands from APCs bind to receptors on T-cells (in trans) to trigger intracellular signaling. A largely overlooked fact is that many receptors often co-exist with ligands on T-cells and APCs, including PD-1/PD-L1 and CD28/B7.1. Using novel reconstitution approaches, we recently discovered that co-expressed PD- 1 and PD-L1 bind to each other in cis and this cis interaction competes with their trans interaction to inhibit PD-1 signaling. We hypothesize that cis interaction occurs with many other ligand-receptor pairs and may regulate other aspects of tumor immunity by perturbing their trans interactions. We are currently using our robust reconstitution systems to ask whether other immunoreceptors and ligands interact in cis and how the putative cis interaction affect their trans interactions. Specifically, to detect cis interaction, we co-attach the ligand and receptor to liposomes, and probe their cis interaction using a fluorescence resonance energy transfer (FRET) readout. To detect trans interaction, we have developed a liposome-lipid bilayer conjugation assay, in which binding between ligand- labeled liposomes and receptor-labeled supported lipid bilayer (SLB) is used as an index for trans interaction. To determine whether cis interaction inhibits trans interaction, we ask in the liposome-bilayer system if addition of receptor on liposomes decreases liposome-SLB conjugation. Our preliminary data revealed that CD28 only binds B7.1 in trans, but not in cis. In contrast, PD-1 binds with PD-L1 both in cis and trans, and the two modes of interaction compete with each other. Further experiments in cells confirmed our finding in vitro, demonstrating the utility of our cell-free reconstitution systems in detecting cis and trans interaction of T-cell co-receptors. Insights from this study will help us clarify the ligand-receptor interaction network at the immunological synapse. Citation Format: Yunlong Zhao, Enfu Hui. Cell-free membrane reconstitution system for cis and trans interaction of T-cell co-receptors and ligands [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A226.","PeriodicalId":170885,"journal":{"name":"Regulating T-cells and Their Response to Cancer","volume":"88 4 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regulating T-cells and Their Response to Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-A226","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Immunotherapy, which harnesses the immune system to combat cancers, is a paradigm-shifting approach in oncology. One important branch of immunotherapy is to use drugs to perturb molecular interactions at the T-cell–antigen presenting cell (APC) interface. In particular, antibodies that block the T-cell coinhibitory receptor PD-1 or its ligand PD-L1 have produced unprecedented clinical activities against a subset of human cancers in a fraction of patients. Extending immunotherapy to a larger patient population requires a better understanding of the interaction network at the T-cell-APC interface. Typically, it is believed that ligands from APCs bind to receptors on T-cells (in trans) to trigger intracellular signaling. A largely overlooked fact is that many receptors often co-exist with ligands on T-cells and APCs, including PD-1/PD-L1 and CD28/B7.1. Using novel reconstitution approaches, we recently discovered that co-expressed PD- 1 and PD-L1 bind to each other in cis and this cis interaction competes with their trans interaction to inhibit PD-1 signaling. We hypothesize that cis interaction occurs with many other ligand-receptor pairs and may regulate other aspects of tumor immunity by perturbing their trans interactions. We are currently using our robust reconstitution systems to ask whether other immunoreceptors and ligands interact in cis and how the putative cis interaction affect their trans interactions. Specifically, to detect cis interaction, we co-attach the ligand and receptor to liposomes, and probe their cis interaction using a fluorescence resonance energy transfer (FRET) readout. To detect trans interaction, we have developed a liposome-lipid bilayer conjugation assay, in which binding between ligand- labeled liposomes and receptor-labeled supported lipid bilayer (SLB) is used as an index for trans interaction. To determine whether cis interaction inhibits trans interaction, we ask in the liposome-bilayer system if addition of receptor on liposomes decreases liposome-SLB conjugation. Our preliminary data revealed that CD28 only binds B7.1 in trans, but not in cis. In contrast, PD-1 binds with PD-L1 both in cis and trans, and the two modes of interaction compete with each other. Further experiments in cells confirmed our finding in vitro, demonstrating the utility of our cell-free reconstitution systems in detecting cis and trans interaction of T-cell co-receptors. Insights from this study will help us clarify the ligand-receptor interaction network at the immunological synapse. Citation Format: Yunlong Zhao, Enfu Hui. Cell-free membrane reconstitution system for cis and trans interaction of T-cell co-receptors and ligands [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A226.
A226: t细胞共受体和配体顺式和反式相互作用的无细胞膜重构系统
利用免疫系统对抗癌症的免疫疗法是肿瘤学领域的一种范式转换方法。免疫治疗的一个重要分支是使用药物来干扰t细胞-抗原提呈细胞(APC)界面的分子相互作用。特别是,阻断t细胞共抑制受体PD-1或其配体PD-L1的抗体已经在一小部分患者中对人类癌症子集产生了前所未有的临床活性。将免疫治疗扩展到更大的患者群体需要更好地了解t细胞- apc界面的相互作用网络。通常,人们认为apc的配体与t细胞上的受体结合(反式)以触发细胞内信号传导。一个很大程度上被忽视的事实是,许多受体通常与配体共存于t细胞和apc上,包括PD-1/PD-L1和CD28/B7.1。利用新的重组方法,我们最近发现共表达的PD-1和PD- l1以顺式方式相互结合,这种顺式相互作用与它们的反式相互作用竞争,从而抑制PD-1信号传导。我们假设顺式相互作用与许多其他配体-受体对发生,并可能通过干扰它们的反式相互作用来调节肿瘤免疫的其他方面。我们目前正在使用我们强大的重构系统来询问其他免疫受体和配体是否以顺式相互作用以及假定的顺式相互作用如何影响它们的反式相互作用。具体来说,为了检测顺式相互作用,我们将配体和受体共同附着在脂质体上,并使用荧光共振能量转移(FRET)读数来探测它们的顺式相互作用。为了检测反式相互作用,我们开发了一种脂质体-脂质双分子层结合试验,其中配体标记的脂质体和受体标记的支持脂质双分子层(SLB)之间的结合被用作反式相互作用的指标。为了确定顺式相互作用是否抑制反式相互作用,我们在脂质体-双层系统中询问在脂质体上添加受体是否会降低脂质体- slb结合。我们的初步数据显示CD28只结合B7.1的反式,而不是顺式。相反,PD-1以顺式和反式两种方式与PD-L1结合,并且两种相互作用模式相互竞争。进一步的细胞实验证实了我们在体外的发现,证明了我们的无细胞重构系统在检测t细胞共受体的顺式和反式相互作用方面的实用性。这项研究的见解将有助于我们阐明免疫突触的配体-受体相互作用网络。引用格式:赵云龙,惠恩福。t细胞共受体与配体顺式、反式相互作用的无细胞膜重构系统[摘要]。第四届CRI-CIMT-EATI-AACR国际癌症免疫治疗会议:将科学转化为生存;2018年9月30日至10月3日;纽约,纽约。费城(PA): AACR;癌症免疫学杂志2019;7(2增刊):摘要nr A226。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信